Peptides for weight management

Purivial Research Team · Updated July 2026

Shop by goal: Weight management · Recovery · Longevity · Skin

The GLP-1 receptor agonists, tirzepatide, semaglutide, and retatrutide, are the most-studied molecules in weight-management research. Here is what the trials show and how they compare.

What the research shows

In controlled trials, semaglutide (the molecule behind Ozempic and Wegovy) produced roughly 15 percent mean body-weight reduction over 68 weeks. Tirzepatide, a dual GLP-1 and GIP agonist, reached 20.9 percent in the SURMOUNT-1 trial. Retatrutide, a triple agonist, reported 24.2 percent at 48 weeks in Phase 2, the highest figure recorded to date.

How they compare

Semaglutide is the single-receptor, most-validated entry point. Tirzepatide adds a second receptor (GIP) for greater effect. Retatrutide adds a third (glucagon) and is the newest and most potent in trials. All three are sold here for laboratory and research use only.

Verified weight-management peptides

Tirzepatide

Dual GLP-1/GIP agonist, the strongest in head-to-head trials.

from $54 View →

Semaglutide

The household-name GLP-1, the most-studied entry point.

from $35 View →

Retatrutide

Triple agonist, the highest body-weight reduction recorded.

from $59 View →

Every vial verified, batch by batch

Every vial ships with a batch-specific COA, HPLC purity, and mass-spec identity.

Browse the full catalog

FAQ

Which weight-management peptide is strongest?

In trials, retatrutide reported the highest body-weight reduction at 24.2 percent, followed by tirzepatide at 20.9 percent and semaglutide at about 15 percent.

What is the difference between them?

Semaglutide targets one receptor (GLP-1), tirzepatide two (GLP-1 and GIP), and retatrutide three (adding glucagon).

Are these sold for human use?

No. Purivial sells these for laboratory and research use only. They are not for human consumption, and statements have not been evaluated by the FDA.